Sante Capital Fund’s Gilead Sciences GILD Stock Holding History

Sante Capital Fund’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-61,095	Closed	-$3.63M	–	49
2022 Q1	$3.63M	Buy	+61,095	New	+$3.91M	4.05%	3

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sante Capital Fund's GILD Position: Q2 2022 in Review

Sante Capital Fund sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 61,095 shares — an estimated $3.63M sold.

Sante Capital Fund first reported a position in GILD in Q1 2022 and held it in 1 quarter. The position peaked at $3.63M in Q1 2022. 1,603 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

Sante Capital Fund reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
Sante Capital Fund sold 61,095 Gilead Sciences shares in Q2 2022, an estimated $3.63M.
Sante Capital Fund first reported a position in Gilead Sciences in Q1 2022 and held it in 1 quarter.
Sante Capital Fund's Gilead Sciences position peaked at $3.63M in Q1 2022.
1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Sante Capital Fund's 13F filing for Q2 2022, filed 27 Jul 2022.